Profile data is unavailable for this security.
About the company
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
- Revenue in GBP (TTM)8.40m
- Net income in GBP-3.75m
- Incorporated2001
- Employees12.00
- LocationFutura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
- Phone+44 148 368 5670
- Fax+44 148 368 5671
- Websitehttps://www.futuramedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.18m | 21.38m | 17.00 | -- | 6.68 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0023 | 0.00 | -- | -- | 0.00 | -77.79 | -82.19 | -85.95 | -95.97 | -- | -- | -- | -- | -- | -19.94 | 0.4794 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Shield Therapeutics PLC | 20.88m | -36.17m | 23.07m | 73.00 | -- | 42.64 | -- | 1.10 | -0.0477 | -0.0477 | 0.0274 | 0.0007 | 0.4723 | 4.06 | 1.69 | 286,068.50 | -81.80 | -56.68 | -136.41 | -67.44 | 34.65 | 52.20 | -173.18 | -365.89 | 0.8968 | -15.29 | 0.9736 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| Arecor Therapeutics PLC | 4.90m | -8.67m | 28.88m | 50.00 | -- | 4.61 | -- | 5.90 | -0.283 | -0.283 | 0.16 | 0.1658 | 0.3213 | -- | 1.67 | 97,980.00 | -56.84 | -- | -89.06 | -- | -- | -- | -176.89 | -- | 1.27 | -- | 0.0523 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -3.42m | 32.43m | 5.00 | -- | 13.28 | -- | -- | -0.0422 | -0.0422 | 0.00 | 0.0196 | 0.00 | -- | -- | -- | -142.89 | -81.13 | -209.37 | -96.44 | -- | -- | -- | -23,877.73 | -- | -163.36 | -- | -- | -- | -- | -7.14 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 36.26m | 11.00 | -- | 8.28 | -- | 224.34 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.38m | 38.00m | 8.00 | -- | 3.05 | -- | -- | -0.0088 | -0.0088 | 0.00 | 0.0249 | 0.00 | -- | -- | 0.00 | -29.11 | -- | -30.18 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Futura Medical PLC | 8.40m | -3.75m | 100.75m | 12.00 | -- | 12.82 | -- | 12.00 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 134.79m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.30m | 148.85m | 34.00 | -- | 129.72 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lombard Odier Asset Management (Europe) Ltd.as of 13 Nov 2024 | 84.90m | 28.08% |
| UBS Asset Management (UK) Ltd.as of 01 Oct 2024 | 33.46m | 11.06% |
| Janus Henderson Investors UK Ltd.as of 01 Oct 2024 | 28.77m | 9.51% |
| Lombard Odier Asset Management (USA) Corp.as of 01 Oct 2024 | 10.71m | 3.54% |
| Chelverton Asset Management Ltd.as of 31 Mar 2023 | 8.81m | 2.91% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Oct 2024 | 8.10m | 2.68% |
| Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 2021 | 7.94m | 2.63% |
| Unicorn Asset Management Ltd.as of 01 Oct 2024 | 5.75m | 1.90% |
| Bank Vontobel AGas of 01 Oct 2024 | 4.55m | 1.50% |
| Maitland Asset Management (Pty) Ltd.as of 01 Oct 2024 | 4.50m | 1.49% |
